Вы искали: pregnancy testing (Английский - Мальтийский)

pregnancy testing
testijiet tat-tqala

pregnancy testing requirements
Ħtiġijiet għal testijiet ta’ tqala

pregnancy
tqala

pregnancy:
użu fit-tqala

if necessary, pregnancy testing should be undertaken.
jekk ikun meħtieġ, għandu jsir test tat-tqala.

she understands the need and accepts to undergo pregnancy testing every 4 weeks
hi tifhem il-bżonn u taċċetta li jkollha tagħmel test tat-tqala kull 4 ġimgħat

pregnancy testing should be conducted at least prior to treatment with vargatef.
għandu jsir test tat-tqala mill-inqas qabel il-kura b'vargatef.

if necessary, pregnancy testing should be undertaken (see section 4.6).
tqala minħabba l- possibbiltà ta ’ teratoġeniċità, thelin m’ għandux jinbeda f’ nisa li jista ’ jkollhom it- tfal, ħlief jekk ma jużawx kontraċezzjoni affidabbli jekk ikun meħtieġ, għandu jsir test tat- tqala (ara sezzjoni 4. 6).

women of childbearing potential should undergo pregnancy testing before initiation of atripla.
nisa li jistgħu joħorġu tqal għandu jsirilhom test tat-tqala qabel tinbeda atripla.

exclusion of pregnancy prior to treatment initiation and monthly pregnancy testing during treatment.
għandha tiġi eskluża t-tqala qabel ma tinbeda l-kura u għandhom isiru testijiet tat-tqala kull xahar waqt il-kura.

ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day.
idealment, l- ittestjar għat-tqala, il-ħruġ tar-riċetta u l-għoti tal-mediċina għandhom iseħħu fl-istess jum.

this shall assist with patient categorisation, and determination of required pregnancy prevention and testing measures.
dan għandu jgħin il-kategorizzazzjoni tal-pazjenti, u d-determinazzjoni tal-miżuri meħtieġa tal-prevenzjoni tat-tqala tal-ittestjar.

patients who present with amenorrhoea during treatment with erivedge should continue monthly pregnancy testing while on treatment.
pazjenti li waqt il-kura b’erivedge ma jkollhomx pirjid mestrwali għandhom ikomplu jittestjaw għat-tqala kull xahar waqt il- kura.

in addition the systemic exposure to bromfenac is negligible; for this reason no pregnancy testing or contraceptive measures are required.
barra minn dan, l-espożizzjoni sistemika għal bromfenac hi negliġibbli; għalhekk m’hemm bżonn l-ebda ttestjar għat-tqala jew miżuri kontraċettivi.

algorithm for pregnancy prevention plan implementation this shall assist with patient categorisation, and determination of required pregnancy prevention and testing measures.
o teratogeniċità u l- bżonn li tiġi evitata espożizzjoni tal- fetu o l- obbligi tal- professjonist tal- kura tas- saħħa li biħsiebu jippreskrivi jew jagħti thalidomide celgene inkluż ■ il- ħtieġa li jingħata parir komprensiv u servizz ta 'pariri lil pazjenti

refer to the summary of product characteristics for peginterferon alfa and ribavirin, including pregnancy testing requirements (see section 4.6).
ara s-sommarju tal-karatteristiċi tal-prodott ta’ peginterferon alfa u ribavirin, inkluż il-ħtieġa ta’ ittestjar għat-tqala (ara sezzjoni 4.6).

the educational materials will reinforce the warnings about the teratogenicity of mycophenolate, provide advice on contraception before therapy is started and guidance on the need for pregnancy testing.
il-materjal edukattiv se jsaħħaħ it-twissijiet dwar it-teratoġeniċità ta’ mycophenolate, jipprovdi parir dwar kontraċezzjoni qabel tinbeda t-terapija u gwida dwar il-ħtieġa ta’ testijiet tat-tqala.

as lenalidomide may be used in combination with kyprolis, particular attention to the lenalidomide pregnancy testing and prevention requirements is needed (see section 4.6).
minħabba li lenalidomide jista’ jintuża flimkien ma’ kyprolis, trid tingħata attenzjoni partikolari lir-rekwiżiti tal-ittestjar u l-prevenzjoni tat-tqala ta’ lenalidomide (ara sezzjoni 4.6).

when lenalidomide is used, particular attention to pregnancy testing and prevention requirements is needed (see “pregnancy and breast-feeding” in this section).
meta jintuża lenalidomide, hemm bżonn ta’ attenzjoni partikolari għal testijiet tat-tqala u r-rekwiżiti tal-prevenzjoni (ara “tqala u treddigħ” f’din is-sezzjoni).

the patient must be advised that if there is any delay in onset of menses or any other reason to suspect pregnancy, they must notify the physician immediately for pregnancy testing, and if positive, the physician and patient must discuss the risk to the pregnancy.
il-pazjenta għandha tingħata l-parir li jekk jittardjalha l-pirjid, jew għal xi raġuni oħra tissusspetta li hija tqila, għandha tavża lit-tabib immedjatament biex isirilha test tat-tqala, u jekk dan ikun pożittiv, it- tabib u l-pazjent għandhom jiddiskutu r-riskju għat-tqala.